Abstract:Li-Fraumeni syndrome (LFS) is a highly penetrant cancer predisposition disorder caused by germline variants in the TP53 tumor suppressor gene. LFS has recently been redefined as a 'spectrum' disorder to reflect the highly variable cancer types with largely unpredictable ages-of-onset and disease severity. The broad functional gradient associated with different TP53 variants is thought to contribute to LFS heterogeneity, although it is still poorly understood and there is an unmet clinical need for risk stratification strategies to improve variant interpretation and patient care. Here, we performed an unsupervised cluster analysis leveraging p53 mutagenesis datasets (Kato et al., 2003 & Giacomelli et al., 2018) that revealed five TP53 mutational clusters with unique mutation patterns, structural features, and functional consequences. Stratifying germline carriers based on the five clusters exposed important clinical characteristics to consider for patient management, such as ages-of-onset, tumor type development, and survival outcomes. In particular, we discovered an osteosarcoma-prone subgroup comprised of monomeric mutant p53 carriers with aggressive cancer phenotypes. We also identified a cluster of TP53 variants found more often in non-cancer and healthy older populations, and carriers of these variants that developed cancer had less "LFS-like" phenotypes including an older age-of-onset and a significantly higher frequency of colorectal cancers. Remarkably, our TP53 variant clustering strategy could also stratify breast cancer survival among germline carriers. This work provides a new framework to delineate the LFS spectrum toward the development of machine learning-based approaches for personalized cancer surveillance plans. Citation Format: Nicholas W. Fischer, Brianne Laverty, Ran Kafri, Kara N. Maxwell, Emma R. Woodward, Christian Kratz, David Malkin. TP53 mutational clusters stratify the Li-Fraumeni syndrome spectrum [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6198.

Tricuspid mass-curious case of Li-Fraumeni syndrome: A case report

Undifferentiated Pleomorphic Sarcoma of the Spine in a patient with Li-Fraumeni syndrome: a case report

Her2-positive breast cancer in a young patient with Li-Fraumeni syndrome: A comprehensive case study

Hematologic malignancies in Li–Fraumeni syndrome: A case report

A Case of Tuberous Sclerosis Complex Associated Lymphangioleiomyomatosis and Review of Literatures

A Rhabdomyosarcoma Patient from a Li-Fraumeni Syndrome Family: a Case Report and Literature Review

A Novel Variant in the TP53 Gene Causing Li-Fraumeni Syndrome

Li-Fraumeni Syndrome: Imaging Features and Guidelines

Histopathologic features of breast cancer in Li-Fraumeni syndrome

Synchronous choroid plexus papilloma and Wilms tumor in a girl, disclosing a Li-Fraumeni syndrome

Li-Fraumeni syndrome presenting with de novo TP53 mutation, severe phenotype and advanced paternal age: a case report

Current insights and future directions of Li-Fraumeni syndrome

Orthopedic manifestations of Li-Fraumeni syndrome: Prevention and treatment of a polymorphic spectrum of malignancies

Abstract 6198: TP53 mutational clusters stratify the Li-Fraumeni syndrome spectrum

Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome

Tumor-like Tricuspid Myxomatus Degeneration with a Primary Cardiac Leiomyoma: A Rare Case Report.

Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA

Patterns of Growth of Tumors in Li-Fraumeni Syndrome by Imaging: A Case Series

Tumor Spectrum and Temporal Cancer Trends in adult carriers of Li-Fraumeni syndrome: Implications for Personalized Screening Strategies in TP53 R337H carriers

Case Report of A Li-Fraumeni Syndrome-Like Phenotype with A De Novo Mutation in Chek2

p.L105Vfs mutation in a family with thymic neuroendocrine tumor combined with MEN1: a case report